ISSN: 1751-2433

Journal Home

Journal Guideline

Expert Review of Clinical Pharmacology Q1 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Review of Clinical Pharmacology is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology (medical) with an H index of 67. It has a price of 2480 €. It has an SJR impact factor of 1,072 and it has a best quartile of Q1. It has an SJR impact factor of 1,072.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Pharmacology (medical) (Q1) Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q1)

Price

2480 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,072

SJR Impact factor

67

H Index

110

Total Docs (Last Year)

370

Total Docs (3 years)

7790

Total Refs

1341

Total Cites (3 years)

339

Citable Docs (3 years)

3.02

Cites/Doc (2 years)

70.82

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

MMWR. Morbidity and mortality weekly report Q1
Annual Review of Public Health Q1
Annual Review of Clinical Psychology Q1
Journal of Thoracic Oncology Q1
Lancet Digital Health, The Q1

Compare this journals

Aims and Scope

Best articles by citations

Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease

Estetrol (E4): the new estrogenic component of combined oral contraceptives

Detection of hydrogen sulfide in biological samples: current and future

Anti-inflammatory drugs as moderators of antidepressant effects, especially those of the selective serotonin-reuptake inhibitor class

Building a better understanding of the burden of disease in familial chylomicronemia syndrome

Green pharmacy and pharmEcovigilance: prescribing and the planet

Unconventional therapies for hidradenitis suppurativa

Carbamazepine adverse drug reactions

Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy forHelicobacter pylorieradication?

Risks and safety of combination therapy for hypothyroidism

Possible dose-side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia

Pros and cons of methods used for the prediction of oral drug absorption

SHOW MORE ARTICLES

Dearth of clinically useful diagnostics limits growth of personalized medicine

Recent advances in medicines for children and neonates

Tipranavir: a novel protease inhibitor for HIV therapy

Pharmacodynamics of bisphosphonates in arthritis

Pharmacologic therapy and the impact on falls in the elderly

Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis

White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs

Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs

Methodologies used to identify and characterize interactions among antiepileptic drugs

Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes